VAX-31
Vaxcyte Announces Positive Phase 1/2 Results for VAX-31, Advances to Phase 3
Vaxcyte, VAX-31, pneumococcal conjugate vaccine, Phase 1/2 study, Phase 3 program, vaccine development, bacterial diseases
Vaxcyte Advances 31-Valent Pneumococcal Vaccine to Phase 3 Trials Following Positive Phase 1/2 Results
Vaxcyte, VAX-31, Pneumococcal Vaccine, Phase 3 Trials, Invasive Pneumococcal Disease, Vaccine Development